AU2015212787B2 - Chimeric protein composed of NGF antagonist domain and a TNFA antagonist domain - Google Patents

Chimeric protein composed of NGF antagonist domain and a TNFA antagonist domain Download PDF

Info

Publication number
AU2015212787B2
AU2015212787B2 AU2015212787A AU2015212787A AU2015212787B2 AU 2015212787 B2 AU2015212787 B2 AU 2015212787B2 AU 2015212787 A AU2015212787 A AU 2015212787A AU 2015212787 A AU2015212787 A AU 2015212787A AU 2015212787 B2 AU2015212787 B2 AU 2015212787B2
Authority
AU
Australia
Prior art keywords
amino acid
ngf
seq
acid sequence
tnfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015212787A
Other languages
English (en)
Other versions
AU2015212787A1 (en
Inventor
Iain Patrick Chessell
Jonathan HATCHER
David Lowe
Darren Schofield
Matthew Alexander Sleeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2015212787A1 publication Critical patent/AU2015212787A1/en
Application granted granted Critical
Publication of AU2015212787B2 publication Critical patent/AU2015212787B2/en
Priority to AU2020230316A priority Critical patent/AU2020230316B2/en
Priority to AU2023285832A priority patent/AU2023285832A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015212787A 2014-02-02 2015-02-02 Chimeric protein composed of NGF antagonist domain and a TNFA antagonist domain Active AU2015212787B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020230316A AU2020230316B2 (en) 2014-02-02 2020-09-11 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
AU2023285832A AU2023285832A1 (en) 2014-02-02 2023-12-21 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934828P 2014-02-02 2014-02-02
US61/934,828 2014-02-02
PCT/EP2015/052098 WO2015114150A1 (en) 2014-02-02 2015-02-02 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020230316A Division AU2020230316B2 (en) 2014-02-02 2020-09-11 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Publications (2)

Publication Number Publication Date
AU2015212787A1 AU2015212787A1 (en) 2016-09-08
AU2015212787B2 true AU2015212787B2 (en) 2020-06-18

Family

ID=52440681

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015212787A Active AU2015212787B2 (en) 2014-02-02 2015-02-02 Chimeric protein composed of NGF antagonist domain and a TNFA antagonist domain
AU2020230316A Active AU2020230316B2 (en) 2014-02-02 2020-09-11 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
AU2023285832A Pending AU2023285832A1 (en) 2014-02-02 2023-12-21 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020230316A Active AU2020230316B2 (en) 2014-02-02 2020-09-11 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
AU2023285832A Pending AU2023285832A1 (en) 2014-02-02 2023-12-21 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Country Status (21)

Country Link
US (5) US9884911B2 (enExample)
EP (2) EP3696193A1 (enExample)
JP (4) JP6687526B2 (enExample)
KR (1) KR102489452B1 (enExample)
CN (2) CN106459190A (enExample)
AU (3) AU2015212787B2 (enExample)
CA (1) CA2938066C (enExample)
CY (1) CY1123248T1 (enExample)
DK (1) DK3099713T3 (enExample)
ES (1) ES2784238T3 (enExample)
HR (1) HRP20200477T1 (enExample)
HU (1) HUE048478T2 (enExample)
LT (1) LT3099713T (enExample)
MX (1) MX382763B (enExample)
PL (1) PL3099713T3 (enExample)
PT (1) PT3099713T (enExample)
RS (1) RS60156B1 (enExample)
RU (1) RU2678810C2 (enExample)
SI (1) SI3099713T1 (enExample)
SM (1) SMT202000182T1 (enExample)
WO (1) WO2015114150A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102489452B1 (ko) 2014-02-02 2023-01-16 메디뮨 리미티드 Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US11572395B2 (en) 2017-09-21 2023-02-07 Merck Patent Gmbh Fusion protein comprising an FGF-18 moiety
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
US20240026036A1 (en) * 2020-09-28 2024-01-25 Medimmune Limited Compounds and methods for treating pain
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
TWI821881B (zh) * 2021-01-29 2023-11-11 醫研生物科技有限公司 腫瘤壞死因子α重組抗體及其用途
CN116179667A (zh) * 2022-09-21 2023-05-30 福建中妆技术研究有限公司 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004726A1 (ja) * 2009-07-07 2011-01-13 住友電気工業株式会社 窒化物半導体基板の製造方法
WO2012162561A2 (en) * 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
NZ529612A (en) 2001-05-30 2006-03-31 Genentech Inc Anti-NGF antibodies for the treatment of various disorders
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
PT1556083E (pt) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
PT1846451E (pt) 2005-01-24 2013-08-28 Elan Pharma Int Ltd Membros de ligação específica para ngf
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101802197A (zh) * 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
SG184473A1 (en) * 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
WO2013101972A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112015023557A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligações dual específicas direcionadas contra tnfa
KR102489452B1 (ko) * 2014-02-02 2023-01-16 메디뮨 리미티드 Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20210009671A1 (en) 2019-05-10 2021-01-14 Medimmune Limited Compounds and methods for treating pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004726A1 (ja) * 2009-07-07 2011-01-13 住友電気工業株式会社 窒化物半導体基板の製造方法
WO2012162561A2 (en) * 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence

Also Published As

Publication number Publication date
AU2020230316B2 (en) 2023-10-05
CN118085103A (zh) 2024-05-28
PT3099713T (pt) 2020-04-16
SMT202000182T1 (it) 2020-05-08
RU2678810C2 (ru) 2019-02-01
RU2016132370A (ru) 2018-03-07
JP2022106951A (ja) 2022-07-20
US20180222971A1 (en) 2018-08-09
EP3099713A1 (en) 2016-12-07
MX2016010030A (es) 2017-04-27
CA2938066C (en) 2025-05-06
US10457728B2 (en) 2019-10-29
CN106459190A (zh) 2017-02-22
RU2019102141A (ru) 2019-03-22
KR20160113711A (ko) 2016-09-30
EP3696193A1 (en) 2020-08-19
US9884911B2 (en) 2018-02-06
JP7074792B2 (ja) 2022-05-24
AU2023285832A1 (en) 2024-03-14
US11053307B2 (en) 2021-07-06
PL3099713T3 (pl) 2020-06-29
JP7520070B2 (ja) 2024-07-22
DK3099713T3 (da) 2020-04-14
WO2015114150A1 (en) 2015-08-06
US20210347871A1 (en) 2021-11-11
ES2784238T3 (es) 2020-09-23
RS60156B1 (sr) 2020-05-29
AU2020230316A1 (en) 2020-10-01
JP2017509323A (ja) 2017-04-06
US20150274818A1 (en) 2015-10-01
JP6687526B2 (ja) 2020-04-22
HRP20200477T1 (hr) 2020-06-26
RU2016132370A3 (enExample) 2018-03-21
AU2015212787A1 (en) 2016-09-08
HUE048478T2 (hu) 2020-08-28
JP2020120666A (ja) 2020-08-13
SI3099713T1 (sl) 2020-06-30
KR102489452B1 (ko) 2023-01-16
MX382763B (es) 2025-03-13
BR112016017698A2 (pt) 2017-10-10
LT3099713T (lt) 2020-07-10
EP3099713B1 (en) 2020-01-15
JP2024133644A (ja) 2024-10-02
CA2938066A1 (en) 2015-08-06
US20200123241A1 (en) 2020-04-23
US11897949B2 (en) 2024-02-13
CY1123248T1 (el) 2021-10-29
US20240262902A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
US11897949B2 (en) Compounds and methods for treating pain
US20210009671A1 (en) Compounds and methods for treating pain
US20240026036A1 (en) Compounds and methods for treating pain
RU2788122C2 (ru) Химерный белок, составленный из домена антагониста NGF и домена антагониста TNFα
HK40028980A (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
HK1231905B (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
HK1231905A1 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
BR112016017698B1 (pt) Molécula ligante, polinucleotídeo isolado, vetor, microrganismo transgênico, composição, kit, e, uso de uma molécula ligante
HK1234753A1 (en) Compositions and methods for treating pain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)